Meral Torun Bayram

Meral Torun Bayram

Auto-generated profile, based on publicly available information

Meral Torun Bayram

Department of Pediatric Nephrology Dokuz Eylül University Medical Faculty İzmir Turkey

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2015 in Rheumatology International
Verified
Journal Article
Open access
PDF file
MBMeral Torun Bayram
Meral Torun Bayram
TÇTufan Çankaya
Tufan Çankaya
EBElçin Bora
Elçin Bora
SKSalih Kavukçu
Salih Kavukçu
AÜAyfer Ülgenalp
Ayfer Ülgenalp
MTMehmet Türkmen
Mehmet Türkmen
Familial Mediterranean fever (FMF) is the most common autosomal recessive inherited inflammatory disease characterized by attacks of painful inflammation. Some patients with FMF have subclinical inflammation persisting between the attacks. We aimed to identify the demographic, clinical and genetic risk factors for subclinical inflammation in children with FMF. The medical records of the children with FMF were evaluated retrospectively for acute-phase response along with gender, age at the onset of symptoms and at the time of diagnosis, clinical signs and symptoms, the presence of amyloidosis and MEFV genotype. Patients with persistently elevated acute-phase response between the attacks were considered to have subclinical inflammation. Patients with or without subclinical inflammation (Group 1 and Group 2, respectively) were compared for the parameters defined above. Independent risk factors for subclinical inflammation were identified by multivariate logistic regression analysis. There were 105 children (male/female: 52/53) who were compliant on colchicine treatment. Subclinical inflammation was detected in 22 (20 %) patients. Group 1 had significantly higher rate of myalgia, arthritis/arthralgia, erysipelas like erythema, amyloidosis, protracted febrile myalgia and M694V mutation compared with Group 2. However, only the presence of myalgia and erysipelas like erythema were found to be independent risk factors for subclinical inflammation (OR 9.8 and 5.9, respectively). Children with FMF who have myalgia and erysipelas like erythema during the attacks are particularly at risk of ongoing inflammation and should be closely monitored for subclinical inflammation even during attack-free periods.

19 July 2019 in Rheumatology International
Verified
Journal Article
Closed access
ASAlper Soylu
Alper Soylu
GYgizem yildiz
gizem yildiz
MBMeral Torun Bayram
Meral Torun Bayram
SKSalih Kavukçu
Salih Kavukçu

1 February 2014 in Urology
Verified
Journal Article
Closed access
MBMeral Torun Bayram
Meral Torun Bayram
DADemet Alaygut
Demet Alaygut
ASAlper Soylu
Alper Soylu
ESErkin Serdaroğlu
Erkin Serdaroğlu
HÇHandan Çakmakçı
Handan Çakmakçı
SKSalih Kavukçu
Salih Kavukçu

30 November 2021 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
MBMeral Torun Bayram
Meral Torun Bayram
CHCihan Heybeli
Cihan Heybeli
GYGizem Yıldız
Gizem Yıldız
ASAlper Soylu
Alper Soylu
ACAli Celik
Ali Celik
SKSalih Kavukçu
Salih Kavukçu

1 April 2014 in Urology
Verified
Journal Article
Closed access
MBMeral Torun Bayram
Meral Torun Bayram
SKSalih Kavukcu
Salih Kavukcu
DADemet Alaygut
Demet Alaygut
ASAlper Soylu
Alper Soylu
HÇHandan Çakmakcı
Handan Çakmakcı

25 October 2020 in The Turkish Journal of Pediatrics
Verified
Journal Article
Open access
MBMeral Torun Bayram
Meral Torun Bayram
ASAlper Soylu
Alper Soylu
SKSalih Kavukçu
Salih Kavukçu
Background. Rituximab is effective for treatment of children with refractory nephrotic syndrome (NS). However, the drug may cause serum sickness characterized by fever, rash, and arthralgia 10-14 days after primary antigen exposure or within a few days after secondary antigen exposure. Rituximab may also lead to anaphylaxis. It is important to recognize rituximab-induced serum sickness (RISS) clinically, as it may mimic various infectious or vasculitic diseases. Case. A six-year-old male with NS treated with rituximab presented with diffuse arthralgia and myalgia eight days after the first dose. He developed an urticarial rash and arthralgia one week after the second dose, while he had swelling of lips and periorbital regions, choking sensation and erythematous rash in whole body within minutes after the third dose of rituximab. The first two reactions resemble typical serum sickness whereas the third reaction seem to be an anaphylaxis/anaphylactoid reaction. Conclusions. Although rituximab-induced serum sickness is typically self-limited, further infusions of rituximab should be avoided as it may provoke more severe symptoms. Most of the previous reported cases of RISS are patients with autoimmune or hematologic disorders. We present the first pediatric case with membranous nephropathy and RISS. The patient also developed anaphylactoid reaction during the third rituximab infusion.